Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma

Simone Oldani, Natalie Prinzi, Federica Morano, Sara Cingarlini, Anna Maria Di Giacomo, Monica Niger, Michele Prisciandaro, Alessandra Raimondi, Giovanni Randon, Chiara Carlotta Pircher, Michele Borghesani, Monica Valente, Elvira Rostanzo, Massimo Milione, Giovanna Sabella, Tommaso Cascella, Filippo Ghelardi, Carolina Sciortino, Eleonora Gusmaroli, Vincenzo Nasca, Filippo de Braud, Filippo Pietrantonio, Sara Pusceddu

Open source

DOI: 10.1080/14796694.2025.2514402
Published: 2025-06-12
Container: Future Oncology
Publisher: Informa UK Limited
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2025.2514402,
  title = {Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma},
  author = {Simone Oldani and Natalie Prinzi and Federica Morano and Sara Cingarlini and Anna Maria Di Giacomo and Monica Niger and Michele Prisciandaro and Alessandra Raimondi and Giovanni Randon and Chiara Carlotta Pircher and Michele Borghesani and Monica Valente and Elvira Rostanzo and Massimo Milione and Giovanna Sabella and Tommaso Cascella and Filippo Ghelardi and Carolina Sciortino and Eleonora Gusmaroli and Vincenzo Nasca and Filippo de Braud and Filippo Pietrantonio and Sara Pusceddu},
  year = {2025},
  journal = {Future Oncology},
  doi = {10.1080/14796694.2025.2514402},
  url = {https://doi.org/10.1080/14796694.2025.2514402}
}

RIS

TY  - JOUR
TI  - Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma
AU  - Simone Oldani
AU  - Natalie Prinzi
AU  - Federica Morano
AU  - Sara Cingarlini
AU  - Anna Maria Di Giacomo
AU  - Monica Niger
AU  - Michele Prisciandaro
AU  - Alessandra Raimondi
AU  - Giovanni Randon
AU  - Chiara Carlotta Pircher
AU  - Michele Borghesani
AU  - Monica Valente
AU  - Elvira Rostanzo
AU  - Massimo Milione
AU  - Giovanna Sabella
AU  - Tommaso Cascella
AU  - Filippo Ghelardi
AU  - Carolina Sciortino
AU  - Eleonora Gusmaroli
AU  - Vincenzo Nasca
AU  - Filippo de Braud
AU  - Filippo Pietrantonio
AU  - Sara Pusceddu
PY  - 2025
JO  - Future Oncology
DO  - 10.1080/14796694.2025.2514402
UR  - https://doi.org/10.1080/14796694.2025.2514402
ER  -

APA

Oldani, S., Prinzi, N., Morano, F., Cingarlini, S., Giacomo, A. M. D., Niger, M., Prisciandaro, M., Raimondi, A., Randon, G., Pircher, C. C., Borghesani, M., Valente, M., Rostanzo, E., Milione, M., Sabella, G., Cascella, T., Ghelardi, F., Sciortino, C., Gusmaroli, E., Nasca, V., Braud, F. D., Pietrantonio, F., & Pusceddu, S. (2025). Design and rationale of the phase II PANDORA trial: first line chemo-immunotherapy in advanced Merkel cell carcinoma. Future Oncology. https://doi.org/10.1080/14796694.2025.2514402

Source records

crossref · retrieved 2026-09-26T12:36:01.940Z